<- Go Home
BrainsWay Ltd.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Market Cap
ILS 291.0M
Volume
53.9K
Cash and Equivalents
ILS 67.9M
EBITDA
ILS 3.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
ILS 34.3M
Profit Margin
74.52%
52 Week High
ILS 8.38
52 Week Low
ILS 4.33
Dividend
N/A
Price / Book Value
4.56
Price / Earnings
69.45
Price / Tangible Book Value
4.56
Enterprise Value
ILS 219.1M
Enterprise Value / EBITDA
57.60
Operating Income
ILS 1.9M
Return on Equity
9.62%
Return on Assets
1.32
Cash and Short Term Investments
ILS 78.0M
Debt
ILS 6.1M
Equity
ILS 68.1M
Revenue
ILS 46.1M
Unlevered FCF
ILS 10.4M
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium